Ignite Creation Date:
2025-12-24 @ 3:32 PM
Ignite Modification Date:
2025-12-26 @ 12:45 AM
Study NCT ID:
NCT01952392
Status:
COMPLETED
Last Update Posted:
2017-02-24
First Post:
2013-08-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AReMIS
Brief Summary:
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
Detailed Description:
AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: